Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

Abstract excerpt

) gene is overexpressed. These carcinomas are known as HER2-positive. HER2 overexpression is linked to an aggressive phenotype and a lower rate of disease-free and overall survival. Drugs such as trastuzumab, pertuzumab, lapatinib, neratinib, and the more recent afatinib target the deregulation of HER2 expression. Some authors have attributed somatic mutations in HER2, a role in resistance to anti-HER2 therapy as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Treatment and Pharmacology
• Share to HER2/EGFR in Cancer Research
• Share to Monoclonal and Polyclonal Antibodies Research